DENVER, June 24 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks® technology and product line.
The patent, issued June 1, 2010, covers the AspirinWorks Test and represents the latest addition to Corgenix intellectual property (IP) portfolio. AspirinWorks is the only FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2 (TxA2), the target of aspirin therapy. The test targets a potential global market exceeding 200 million individuals.
U.S. Patent No. 7,727,730 B2, "Methods and Kits for Detection of Thromboxane A2 Metabolites," recognizes the ability of the AspirinWorks Test to accurately measure additional biomarkers of platelet inhibition. Specifically, the patent relates to the AspirinWorks Test's ability to more accurately depict the true levels of circulating TxA2, a chemical that activates platelets and causes them to stick together.
"This patent further strengthens our strategic position in this important aspect of clinical testing," said Douglass Simpson, Corgenix President and Chief Executive Officer. "By adding this patent to our already strong IP portfolio, Corgenix remains in a premier competitive position as this market continues to evolve."
More than 1 million Americans experience new or recurrent heart attacks each year. At-risk individuals are eligible for aspirin therapy and should be tested for the presence or absence of the therapy's effect.
Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor's office or patient service center, making the test convenient for both physician and patient.
Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or
e-mail [email protected]. More information is also available at www.aspirinworks.com.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.
SOURCE Corgenix Medical Corporation
Advertisement
The patent, issued June 1, 2010, covers the AspirinWorks Test and represents the latest addition to Corgenix intellectual property (IP) portfolio. AspirinWorks is the only FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2 (TxA2), the target of aspirin therapy. The test targets a potential global market exceeding 200 million individuals.
Advertisement
U.S. Patent No. 7,727,730 B2, "Methods and Kits for Detection of Thromboxane A2 Metabolites," recognizes the ability of the AspirinWorks Test to accurately measure additional biomarkers of platelet inhibition. Specifically, the patent relates to the AspirinWorks Test's ability to more accurately depict the true levels of circulating TxA2, a chemical that activates platelets and causes them to stick together.
"This patent further strengthens our strategic position in this important aspect of clinical testing," said Douglass Simpson, Corgenix President and Chief Executive Officer. "By adding this patent to our already strong IP portfolio, Corgenix remains in a premier competitive position as this market continues to evolve."
More than 1 million Americans experience new or recurrent heart attacks each year. At-risk individuals are eligible for aspirin therapy and should be tested for the presence or absence of the therapy's effect.
Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor's office or patient service center, making the test convenient for both physician and patient.
Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or
e-mail [email protected]. More information is also available at www.aspirinworks.com.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.
SOURCE Corgenix Medical Corporation
